Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
NCT ID: NCT00137332
Last Updated: 2007-12-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
90 participants
INTERVENTIONAL
2005-11-30
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GAP-486 (ZP-123)
0.9% Sodium Chloride, USP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing an electrophysiology study for evaluation of ventricular rhythm
* Patients with a history of heart disease
Exclusion Criteria
* Patients with certain cardiac risk factors
* Patients with significant kidney or liver problems
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sacramento, California, United States
San Francisco, California, United States
Washington D.C., District of Columbia, United States
Orlando, Florida, United States
Peoria, Illinois, United States
Iowa City, Iowa, United States
Worcester, Massachusetts, United States
Ann Arbor, Michigan, United States
Lansing, Michigan, United States
Southfield, Michigan, United States
Minneapolis, Minnesota, United States
Newark, New Jersey, United States
Winston-Salem, North Carolina, United States
Cleveland, Ohio, United States
Cleveland, Ohio, United States
Hershey, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
Falls Church, Virginia, United States
Norfolk, Virginia, United States
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
St-Johnâ S, Newfoundland and Labrador, Canada
Halifax, Nova Scotia, Canada
London, Ontario, Canada
Newmarket, Ontario, Canada
Toronto, Ontario, Canada
Fleurimont, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Montreal, Quebec, Canada
Sainte-Foy, Quebec, Canada
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3163K1-202
Identifier Type: -
Identifier Source: org_study_id